Physician profile
Jamal Mohammed
NPI 1609364124
$3,904.78
in general payments reported to CMS, 2019-2025
44 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $1,141 · 2023: $911 · 2024: $902 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $291.26 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $278.27 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $273.72 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $263.09 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.40 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $222.86 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $214.23 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $175.50 | 2022-2025 | |
| Abbott Laboratories | $174.71 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Edwards Lifesciences Corporation | $154.97 | 2023-2024 | Sapien 3 Ultra Resilia |
| Aerin Medical INC. | $137.21 | 2023 | |
| Abbvie INC. | $129.19 | 2022-2024 | |
| Horizon Therapeutics Plc | $112.94 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.67 | 2021-2024 | Tradjenta, Synjardy, Jardiance |
| Inspire Medical Systems, INC. | $101.45 | 2024-2025 | Inspire |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $98.15 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $83.03 | 2022-2025 | Capvaxive, Gardasil 9, Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.10 | 2022-2023 | |
| Boston Scientific Corporation | $62.67 | 2023-2024 | Watchman Flx |
| Insmed, INC. | $56.17 | 2024-2025 | Arikayce |
| Esperion Therapeutics, INC. | $50.95 | 2022-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $43.84 | 2022 | |
| Astellas Pharma US INC | $41.90 | 2022-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $39.52 | 2023-2024 | Gattex |
| Otsuka America Pharmaceutical, INC. | $38.59 | 2022-2023 | Rexulti, Abilify Maintena |
| Evoke Pharma, INC. | $38.22 | 2023 | Gimoti |
| Biohaven Pharmaceutical Holding Company LTD. | $29.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.58 | 2023 | Spravato |
| Phathom Pharmaceuticals, INC. | $28.94 | 2024 | Voquezna |
| Tactile Systems Technology INC | $28.89 | 2025 | Nimbl, Flexitouch Plus |
| Sandoz INC. | $28.13 | 2024 | |
| Intra-Sana Laboratories | $27.80 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Teva Pharmaceuticals USA, INC. | $25.00 | 2022 | |
| Nevro Corp. | $24.87 | 2024 | Senza |
| Eisai INC. | $23.93 | 2021 | |
| Allergan, INC. | $21.88 | 2022 | |
| Medtronic, INC. | $21.38 | 2023 | Venaseal |
| Verity Pharmaceuticals INC. | $21.27 | 2025 | Tlando |
| Sumitomo Pharma America, INC. | $18.76 | 2025 | Myfembree |
| Amneal Pharmaceuticals LLC | $18.21 | 2021 | |
| Currax Pharmaceuticals LLC | $16.76 | 2025 | Contrave |
| Amag Pharmaceuticals, INC. | $15.73 | 2021 | |
| Photonicare INC | $15.61 | 2024 | Otosight Middle Ear Scope |
| Seqirus USA INC | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.